A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (NCT04640623)
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease; and disease-free survival (DFS) in participants treated with TAR-200 alone with papillary disease only (Cohort 4).
Who can join: Review the eligibility criteria below.
Location: Del Sol Research Management, LLC — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (144 Sites)
Showing the first 25 of 144 sites.
- Del Sol Research Management, LLC — Tucson, Arizona
- University of Southern California — Los Angeles, California
- Genesis Healthcare Partners - Genesis Research Greater Los Angeles — Sherman Oaks, California
- The Urology Center of Colorado — Denver, Colorado
- Foothills Urology - Golden Off — Golden, Colorado
- DuPage Medical Group — Lisle, Illinois
- Urology of Indiana — Greenwood, Indiana
- Wichita Urology Group — Wichita, Kansas
- Michigan Institute of Urology — Troy, Michigan
- NYU Langone Health — New York, New York
- SUNY Upstate Medical University — Syracuse, New York
- Associated Medical Professionals — Syracuse, New York
- Levine Cancer Institute — Charlotte, North Carolina
- The Urology Group — Cincinnati, Ohio
- Urologic Consultants of Southeastern Pennsylvania — Bala-Cynwyd, Pennsylvania
- Thomas Jefferson University — Philadelphia, Pennsylvania
- Urology Associates, PC — Nashville, Tennessee
- Vanderbilt University Medical Center — Nashville, Tennessee
- Urology Austin — Austin, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
- Urology San Antonio Research — San Antonio, Texas
- Spokane Urology — Spokane, Washington
- Flinders Medical Centre — Bedford Park,
- Eastern Health Research — Box Hill,
- Macquarie University Hospital — Sydney,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Urinary Bladder Neoplasms
- A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder — Loma Linda, California
- A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer — Tucson, Arizona
- A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) — Birmingham, Alabama
- Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) — Washington D.C., District of Columbia
- A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) — Bakersfield, California
Explore by condition: All Urinary Bladder Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.